Propanc Biopharma gets Nasdaq bid price deficiency notice
Nasdaq told Propanc on October 23, 2026 that its stock had failed to maintain the $1.00 minimum bid price, putting the company's listing at risk unless it appeals by October 30.
SEC filing
2 stories
Nasdaq told Propanc on October 23, 2026 that its stock had failed to maintain the $1.00 minimum bid price, putting the company's listing at risk unless it appeals by October 30.
SEC filing
Neogen lifted full-year guidance after first-quarter core revenue grew 8.1% and said Petrifilm manufacturing and a pending Zoetis divestiture remain on schedule.
SEC filing (11)